PAVmed Inc
PAVMZ
NASDAQ Capital Market0.00
USD
+0.00
- -
PAVmed Inc
PAVMZ
(NASDAQ Capital Market)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- PAVmed Inc is a diversified commercial-stage medical technology company that operates through multiple independently financed subsidiaries under a shared services business model. The company’s core products and services span medical devices, diagnostics, and digital health sectors. Its flagship diagnostic products include the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device, which are the first and only commercial technologies for early detection of esophageal precancer to reduce esophageal cancer risk. PAVmed’s majority-owned subsidiary Veris Health focuses on digital health and personalized cancer care through a remote patient monitoring platform with implantable biologic sensors and connected devices. Veris is developing an implantable physiological monitor designed to be used alongside chemotherapy ports, integrating with its cancer care platform. Another subsidiary is Lucid Diagnostics, which commercializes the EsoGuard test and is advancing insurance coverage and market access for this diagnostic solution. PAVmed also operates an incubator subsidiary advancing innovative pipeline technologies such as PortIO, an endoscopic device technology. Recent major developments include the launch of the commercial phase of a strategic partnership with The Ohio State University Comprehensive Cancer Center – James Cancer Hospital to expand deployment of the Veris Cancer Care Platform for enhanced personalized cancer care. Veris has fully relaunched the development of its implantable physiological monitor with plans to submit for FDA 510(k) clearance in 2026. PAVmed signed a letter of intent to license groundbreaking endoscopic esophageal imaging technology through a new subsidiary, expanding its innovation pipeline with additional growth engines. The company successfully restructured its debt in early 2025, significantly reducing liabilities and improving its balance sheet, positioning itself for accelerated commercialization once Medicare coverage for EsoGuard is secured. Geographically, PAVmed operates primarily in the United States with collaborations in leading academic medical centers. Founded in 2012 and headquartered in New York, New York, PAVmed is executing a multi-pronged growth strategy leveraging its shared services model to advance diversified medical technologies addressing unmet clinical needs in cancer diagnostics and digital health management. This overview reflects the most current strategic partnerships, product advances, financial restructuring, and operational focus for PAVmed as of late 2025.